Halozyme Revenue Estimates Fall Below Company Guidance Ahead of Q1 Earnings
Summary
Halozyme Therapeutics is expected to report first-quarter earnings per share of $1.53. Critically, the mean analyst revenue estimate of $359.053 million falls significantly below the company's own guidance range of $406.59 million to $429.18 million, which was provided on February 17, 2026. This divergence suggests a potential revenue miss against company expectations, which could be a negative catalyst for the stock. Traders will be closely watching the actual Q1 results, due on May 11, to assess whether the company meets its own revenue targets or the lower analyst consensus.
At the time of this announcement, HALO was trading at $64.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $47.50 to $82.22. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.